No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q3 2026, worth $682.2K in total; no superinvestor holds it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Tempest Therapeutics, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
SEC filings by Tempest Therapeutics, Inc.
Filed
Form
8-K items
Period
Document
Filing index
Nov 16, 2026
8-KCurrent report
5.07Item 5.07: Results of a shareholder vote8.01Item 8.01: Other events
1.01Item 1.01: Entry into a material definitive agreement5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets3.02Item 3.02: Unregistered sale of equity securities5.01Item 5.01: Change in control of the company5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements9.01Item 9.01: Financial statements and exhibits
3.03Item 3.03: Material modification to the rights of security holders5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.07Item 5.07: Results of a shareholder vote
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement7.01Item 7.01: Regulation FD disclosure8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits